1st Quarter - Amendment

MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$450,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Amendment (this page) Apr 30, 2013 $450,000 Replaced
1st Quarter - Amendment Apr 30, 2013 $450,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

FDA related matters including issues related to "biosimilar products", prescription drug "track and trace" and orphan drug products

LobbyistCovered position, as disclosed
AARTI SHAH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2013 HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs, especially changes to ASP, physician payment and oncology matters

LobbyistCovered position, as disclosed
AARTI SHAH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.Con.Res. 25 (113th), S.Con.Res. 8 (113th), H.R. 933 (113th)

Health Issues HCR

Implementation of the new health care reform law - PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage in the essential benefit package, and other matters.

LobbyistCovered position, as disclosed
AARTI SHAH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Budget/Appropriations BUD

S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2013 HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs

LobbyistCovered position, as disclosed
AARTI SHAH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.Con.Res. 25 (113th), S.Con.Res. 8 (113th), H.R. 933 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.